---
input_text: 'Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor
  discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective
  study in real-world practice. The prognosis of chronic myeloid leukemia has significantly
  improved with the introduction of tyrosine kinase inhibitors (TKIs). However, indefinite
  TKI treatment can lead to adverse effects and high costs. Recent studies have suggested
  that treatment-free remission (TFR) is achievable in patients with a deep molecular
  response (DMR). The present multicenter, retrospective observational study conducted
  in Japan evaluated the applicability of the European LeukemiaNet (ELN) 2020 TKI
  discontinuation criteria, which recommend TKI therapy of >= 5 years with sustained
  MR4 for >= 3 years or MR4.5 for >= 2 years. A total of 100 patients who discontinued
  TKI therapy were analyzed, with 70 meeting the ELN2020 criteria. The overall 12-month
  TFR rate was 71.9 %. Univariate analysis showed that both the duration of DMR and
  TKI therapy were significantly associated with TFR, with hazard ratios (HR) of 0.305
  and 0.450, respectively. Only DMR duration remained significant (HR 0.362) in multivariate
  analysis. Patients who lost MMR after TKI discontinuation rapidly re-achieved molecular
  response upon TKI resumption. The most common reason for TKI discontinuation was
  elective cessation, followed by adverse events, among which pleural effusion due
  to dasatinib was the most frequent. The results of this study, the first to assess
  the ELN2020 criteria in a Japanese cohort, suggest that the criteria are applicable
  in real-world clinical practice.'
raw_completion_output: |-
  primary_disease: Chronic myeloid leukemia
  medical_actions: Tyrosine kinase inhibitor discontinuation; TKI therapy; Treatment-free remission (TFR); Univariate analysis; Multivariate analysis; TKI resumption
  symptoms: Adverse effects; Pleural effusion
  chemicals: Tyrosine kinase inhibitors (TKIs); Dasatinib
  action_annotation_relationships: Tyrosine kinase inhibitor discontinuation PREVENTS adverse effects IN Chronic myeloid leukemia; TKI therapy (with Tyrosine kinase inhibitors) TREATS Chronic myeloid leukemia; TKI resumption TREATS loss of molecular response IN Chronic myeloid leukemia; Tyrosine kinase inhibitor discontinuation TREATS high costs IN Chronic myeloid leukemia; TKI therapy (with Dasatinib) TREATS Chronic myeloid leukemia; TKI therapy (with Dasatinib) CAUSES Pleural effusion IN Chronic myeloid leukemia
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  TKI therapy (with Dasatinib) CAUSES Pleural effusion IN Chronic myeloid leukemia

  ===

extracted_object:
  primary_disease: MONDO:0011996
  medical_actions:
    - Tyrosine kinase inhibitor discontinuation
    - TKI therapy
    - Treatment-free remission (TFR)
    - Univariate analysis
    - Multivariate analysis
    - TKI resumption
  symptoms:
    - Adverse effects
    - HP:0002202
  chemicals:
    - CHEBI:38637
    - CHEBI:190514
  action_annotation_relationships:
    - subject: Tyrosine kinase inhibitor discontinuation
      predicate: PREVENTS
      object: adverse effects
      qualifier: MONDO:0011996
      subject_extension: CHEBI:38637
      object_extension: adverse effects
    - subject: TKI therapy
      predicate: TREATS
      object: HP:0005506
      subject_qualifier: with Tyrosine kinase inhibitors
      subject_extension: CHEBI:38637
    - subject: resumption
      predicate: TREATS
      object: loss of molecular response
      qualifier: MONDO:0011996
      subject_extension: TKI
    - subject: discontinuation
      predicate: TREATS
      object: high costs
      qualifier: MONDO:0011996
      subject_extension: CHEBI:38637
    - subject: TKI therapy
      predicate: TREATS
      object: HP:0005506
      subject_qualifier: with Dasatinib
      subject_extension: CHEBI:190514
    - subject: TKI therapy
      predicate: CAUSES
      object: HP:0002202
      qualifier: MONDO:0011996
      subject_qualifier: with Dasatinib
      subject_extension: CHEBI:190514
named_entities:
  - id: MONDO:0018874
    label: Acute myeloid leukemia (AML)
  - id: HP:0001945
    label: Fever
  - id: HP:0012378
    label: Fatigue
  - id: MONDO:0020512
    label: T cell acute lymphoblastic leukemia (T-ALL)
  - id: HP:0006727
    label: T-ALL
  - id: CHEBI:50131
    label: Decitabine
  - id: CHEBI:133021
    label: Venetoclax
  - id: HP:0004808
    label: Acute myeloid leukemia
  - id: HP:0002090
    label: pneumonia
  - id: HP:0100806
    label: sepsis
  - id: CHEBI:71019
    label: Homoharringtonine
  - id: CHEBI:28680
    label: Cytarabine
  - id: HP:0000739
    label: anxiety
  - id: HP:0000716
    label: depression
  - id: CHEBI:190514
    label: dasatinib
  - id: CHEBI:23456
    label: cyclodextrins
  - id: MAXO:0000747
    label: Hematopoietic Stem Cell Transplantation (HSCT)
  - id: MAXO:0000647
    label: Chemotherapy
  - id: HP:0002018
    label: Nausea
  - id: HP:0002094
    label: Dyspnea
  - id: HP:0100785
    label: Insomnia
  - id: HP:0012531
    label: Pain
  - id: HP:0002019
    label: Constipation
  - id: CHEBI:2038
    label: Azacitidine
  - id: CHEBI:197440
    label: Tumor necrosis factor-alpha (TNF-alpha)
  - id: MONDO:0004967
    label: Acute Lymphoblastic Leukemia (ALL)
  - id: CHEBI:8378
    label: Prednisolone
  - id: HP:0000001
    label: Acute Lymphoblastic Leukemia (ALL)
  - id: HP:0001297
    label: Stroke
  - id: HP:0001635
    label: Heart failure
  - id: HP:0001677
    label: Coronary atherosclerosis
  - id: MONDO:0004992
    label: Cancer
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: MONDO:0004947
    label: B-cell acute lymphoblastic leukemia
  - id: MAXO:0000757
    label: infusion
  - id: MAXO:0000602
    label: Hemodialysis
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002039
    label: Anorexia
  - id: HP:0100519
    label: Anuria
  - id: HP:0011037
    label: Decreased urine output
  - id: HP:0001919
    label: Acute kidney injury
  - id: CHEBI:18332
    label: Levothyroxine
  - id: MONDO:0020511
    label: Acute B-lymphoblastic leukemia (B-ALL)
  - id: HP:0003419
    label: lower back pain
  - id: MONDO:0010651
    label: high-risk myelodysplastic neoplasm (MDS)
  - id: CHEBI:30621
    label: arsenic trioxide
  - id: HP:0002360
    label: sleep disturbances
  - id: MONDO:0017361
    label: Cytokine release syndrome (CRS)
  - id: CHEBI:64360
    label: Tocilizumab
  - id: MONDO:0012883
    label: Acute promyelocytic leukemia (APL)
  - id: MAXO:0000149
    label: Allogeneic hematopoietic cell transplantation (HCT)
  - id: MONDO:0004948
    label: chronic lymphocytic leukemia
  - id: HP:0002014
    label: diarrhea
  - id: CHEBI:63791
    label: lenalidomide
  - id: HP:0005550
    label: chronic lymphocytic leukemia
  - id: MONDO:0003864
    label: Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)
  - id: MAXO:0001298
    label: therapies
  - id: CHEBI:42068
    label: Idarubicin
  - id: HP:0032169
    label: severe infections
  - id: CHEBI:55379
    label: cyclosporine (CsA)
  - id: CHEBI:85010
    label: eltrombopag
  - id: CHEBI:85012
    label: thrombopoietin receptor agonist (TPO-RA)
  - id: MAXO:0001394
    label: oral administration
  - id: MAXO:0001525
    label: intravenous administration
  - id: HP:0002315
    label: Headache
  - id: CHEBI:50858
    label: Corticosteroids
  - id: HP:0100614
    label: myositis
  - id: CHEBI:26708
    label: NA
  - id: CHEBI:76612
    label: Ibrutinib
  - id: CHEBI:167707
    label: Acalabrutinib
  - id: CHEBI:145428
    label: glasdegib
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0010030
    label: bone marrow transplantation
  - id: HP:0001903
    label: anemia
  - id: HP:0001875
    label: neutropenia
  - id: HP:0001698
    label: pericardial effusion
  - id: CHEBI:35705
    label: immunosuppressants
  - id: MONDO:0019460
    label: Acute leukemia of ambiguous lineage (ALAL)
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:62434
    label: FLT3 inhibitor
  - id: CHEBI:38637
    label: Tyrosine kinase inhibitor
  - id: CHEBI:28748
    label: Doxorubicin (Dox)
  - id: HP:0020174
    label: drug resistance
  - id: CHEBI:23888
    label: drugs
  - id: MONDO:0018689
    label: Plasma cell leukemia
  - id: HP:0031047
    label: monoclonal gammopathy
  - id: CHEBI:52726
    label: proteasome inhibitor
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:48120
    label: anthracyclines
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: HP:0001909
    label: leukemia
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0011996
    label: Chronic Myeloid Leukemia
  - id: CHEBI:46345
    label: 5-fluorouracil
  - id: HP:0005506
    label: chronic myeloid leukemia
  - id: MONDO:0005059
    label: Leukemia
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:50729
    label: Mitoxantrone
  - id: CHEBI:50924
    label: Sorafenib
  - id: CHEBI:145372
    label: Gilteritinib
  - id: CHEBI:90217
    label: Quizartinib
  - id: CHEBI:145410
    label: IDH inhibitors
  - id: CHEBI:233585
    label: BAM15
  - id: CHEBI:197439
    label: TNFalpha
  - id: CHEBI:45716
    label: SAHA (Vorinostat)
  - id: HP:0002202
    label: Pleural effusion
